Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

BACKGROUND: Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Harrison K., Lehrer, Jonathan, Alshalalfa, Mohammed, Erho, Nicholas, Davicioni, Elai, Lotan, Tamara L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683385/
https://www.ncbi.nlm.nih.gov/pubmed/29132337
http://dx.doi.org/10.1186/s12885-017-3729-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683385/
https://www.ncbi.nlm.nih.gov/pubmed/29132337
http://dx.doi.org/10.1186/s12885-017-3729-z

Ejemplares similares